ruxolitinib + CMPD1

ruxolitinib + CMPD1 is an experimental small-molecule combination comprising ruxolitinib, an orally bioavailable Janus kinase 1/2 (JAK1/2) inhibitor approved for myelofibrosis and related myeloproliferative neoplasms, and CMPD1, a research-stage p38 mitogen-activated protein kinase inhibitor that has been explored preclinically as a chemosensitizer and signaling-pathway modulator. The combination is conceptually aimed at dual blockade of JAK-STAT and stress-activated MAPK signaling to enhance antitumor or antiproliferative effects and potentially overcome resistance mechanisms seen with JAK inhibition alone, but it remains a preclinical tool combination rather than a developed pharmaceutical product, with no dedicated clinical program or commercial formulation.